PREDICTIVE AND THERAPEUTIC UTILITIES OF EPIGENETIC CHANGES IN CHROMATIN IN MELANO

黑色素染色质表观遗传变化的预测和治疗用途

• 批准号: 7147298
• 负责人: SHERMAN Morton WEISSMAN
• 金额: $ 17.97万
• 依托单位: YALE UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-06-01 至 2011-05-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7147298
• 关键词: DNA; DNA methylation; bioinformatics; chromatin; clinical research; epigenetics; gene expression; genes; melanoma; methylation; neoplasm /cancer

Aberrant changes in gene activity due to chromatin remodeling are frequent in cancer cells. They involve methylation/demethylation of cytosine at cytosine-guanine (CpG) pair rich islands in promoter regions and post-transcriptional modifications (acetylation/methylation) of histones. Aberrant gain or loss of DNA methylation causes altered expression of genes involved in tumorigenesis and maintenance of the malignant phenotype including tumor suppressors, apoptotic factors, DNA repair enzymes, adhesion molecules, and immunomodulators. The reversible nature of epigenetic changes in chromatin is the rationale for clinical development of the DNA demethylation agents 5-Aza-2'-deoxy-cytidine (5-Aza-CdR, also known as decitabine), its analogue 5-azacytidine, and the histone deacetylase (HDAC) inhibitors. Our goal is to identify epigenomic markers associated with growth arrest of melanoma cells and tumors. These markers can be the basis for an assay for predicting responses and tailoring treatment with epigenetic modifiers to responsive patients. In Aim 1 we will assess global changes in gene expression in response to decitabine in sensitive and resistant melanoma cells and determine gene-expression profiles that can predict growth suppression. In Aim 2 we will interrogate genome-wide changes in the patterns of DNA promoter methylation in sensitive and resistant melanoma cells in response to 5-Aza-CdR, and correlate it to the profiles of affected genes revealed in Aim 1. We will also determine the global changes in DNA methylation in melanoma tumors excised from patients undergoing treatment with 5-azacytidine and compare it to melanoma cells in culture. In Aim 3 we will verify the epigenetic modification (DNA methylation) in regulatory regions of 5-Aza-CdRresponsive genes deemed critical to inducing growth arrest. We will employ multiple bioinformatics methods to perform data mining and integration of the information derived from the chromatin modification and gene expression array data. We foresee that the information will help devise a cost-effective epigenetic-modifier test that can predict efficacy and monitor therapeutic responses to this class of agents in melanoma patients. This project includes a Phase I trial with 5-azacytidine, is multidisciplinary, involving the concerted efforts of basic scientists, molecular biologists, bioinformatics and clinical oncologists.

由于染色质重塑导致的基因活性异常变化在癌细胞中是常见的。它们涉及 启动子区中富含胞嘧啶-鸟嘌呤（CpG）对的岛上胞嘧啶的甲基化/去甲基化， 组蛋白的转录后修饰（乙酰化/甲基化）。DNA的异常获得或丢失 甲基化导致参与肿瘤发生的基因表达改变和恶性肿瘤的维持。 表型包括肿瘤抑制因子、凋亡因子、DNA修复酶、粘附分子和 免疫调节剂。染色质表观遗传变化的可逆性是临床应用的基本原理。 DNA去甲基化剂5-氮杂-2 '-脱氧胞苷（5-Aza-CdR，也称为 地西他滨）、其类似物5-氮杂胞苷和组蛋白脱乙酰酶（HDAC）抑制剂。我们的目标是确定 与黑色素瘤细胞和肿瘤生长停滞相关的表观基因组标记物。这些标记可以是 用于预测响应和用表观遗传修饰剂定制治疗以响应 患者在目标1中，我们将评估地西他滨敏感性肿瘤中基因表达的总体变化。 和耐药性黑色素瘤细胞，并确定可以预测生长抑制的基因表达谱。 在目标2中，我们将询问敏感性肿瘤中DNA启动子甲基化模式的全基因组变化， 和抗性黑色素瘤细胞对5-Aza-CdR的反应，并将其与受影响基因的谱相关联 目标1中显示。我们还将确定黑色素瘤肿瘤中DNA甲基化的总体变化 从接受5-氮杂胞苷治疗的患者中切下，并将其与培养物中的黑素瘤细胞进行比较。 在目的3中，我们将验证5-Aza-CdR应答的调控区中的表观遗传修饰（DNA甲基化）。 被认为是诱导生长停滞的关键基因。我们将采用多种生物信息学方法 对来自染色质修饰和基因修饰的信息进行数据挖掘和整合 表达式数组数据。我们预见这些信息将有助于设计出一种具有成本效益的表观遗传修饰剂 测试可以预测疗效和监测治疗反应，这类药物在黑色素瘤患者。 该项目包括5-氮杂胞苷的I期试验，是多学科的，涉及以下方面的共同努力： 基础科学家、分子生物学家、生物信息学家和临床肿瘤学家。